2020 Binge Eating Disorder Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Binge Eating Disorder pipeline report presents a comprehensive overview of the research and development of Binge Eating Disorder drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: One drug in Research phase, five drugs in pre-clinical phase, two drugs in Phase 1, one drug in Phase 3 and one drug in Pre-registration phase
As of February 2020, the Binge Eating Disorder pipeline remains robust with 10 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Binge Eating Disorder treatment. Diverse types of targeted therapies are being explored through clinical trials including Adrenergic uptake inhibitors; Aldehyde dehydrogenase 2 (ALDH2) inhibitors; Glucagon-like peptide 1 (GLP-1) receptor agonist; Orexin-1 Antagonist; PDE7 inhibitor; Trace Amine-Associated Receptor 1 (TAAR1) Agonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Binge Eating Disorder drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Binge Eating Disorder pipeline drugs profiled in the report include- ANS-6637, CT-010018, CTDP-002, RO5256390, Saxenda (liraglutide), OMS527, Orexin-1 Antagonist for Binge Eating Disorder, Orexin-1 Antagonist for Central Nervous System Disorders, dasotraline (SEP360-221), (Phentermine and topiramate)
As of February 2020, the Binge Eating Disorder pipeline remains robust with 10 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Binge Eating Disorder treatment. Diverse types of targeted therapies are being explored through clinical trials including Adrenergic uptake inhibitors; Aldehyde dehydrogenase 2 (ALDH2) inhibitors; Glucagon-like peptide 1 (GLP-1) receptor agonist; Orexin-1 Antagonist; PDE7 inhibitor; Trace Amine-Associated Receptor 1 (TAAR1) Agonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Binge Eating Disorder drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Binge Eating Disorder development
- Binge Eating Disorder pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Binge Eating Disorder pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Binge Eating Disorder pipeline candidates included
- Business overview and snapshot of all companies involved in Binge Eating Disorder pipeline are included
- Latest market and pipeline developments are provided in the report
Binge Eating Disorder pipeline drugs profiled in the report include- ANS-6637, CT-010018, CTDP-002, RO5256390, Saxenda (liraglutide), OMS527, Orexin-1 Antagonist for Binge Eating Disorder, Orexin-1 Antagonist for Central Nervous System Disorders, dasotraline (SEP360-221), (Phentermine and topiramate)
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Binge Eating Disorder Condition
2.3 Binge Eating Disorder Pipeline Snapshot, 2020
2.4 Companies investing in Binge Eating Disorder pipeline therapeutics
2.5 Phase wise Binge Eating Disorder Pipeline Candidates
2.6 Most Researched Mechanism of Action of Binge Eating Disorder Pipeline Products
2.7 Route of Administration of Binge Eating Disorder Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Amygdala Neurosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Chronos Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 F. Hoffmann-La Roche Ltd Overview, Contacts and ASD Pipeline Drugs
3.4 Novo Nordisk AS Overview, Contacts and ASD Pipeline Drugs
3.5 Omeros Corp Overview, Contacts and ASD Pipeline Drugs
3.6 OXonium Therapeutics Overview, Contacts and ASD Pipeline Drugs
3.7 Sosei Heptares Overview, Contacts and ASD Pipeline Drugs
3.8 Sunovion Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Vivus Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 ANS-6637 Drug Details
4.1.1 ANS-6637 Current Status
4.1.2 ANS-6637 Drug Overview
4.1.3 ANS-6637 Mechanism of Action
4.1.4 ANS-6637 Licensing/Collaboration Companies
4.1.5 ANS-6637 Clinical Trials
4.2 CT-010018 Drug Details
4.2.1 CT-010018 Current Status
4.2.2 CT-010018 Drug Overview
4.2.3 CT-010018 Mechanism of Action
4.2.4 CT-010018 Licensing/Collaboration Companies
4.2.5 CT-010018 Clinical Trials
4.3 CTDP-002 Drug Details
4.3.1 CTDP-002 Current Status
4.3.2 CTDP-002 Drug Overview
4.3.3 CTDP-002 Mechanism of Action
4.3.4 CTDP-002 Licensing/Collaboration Companies
4.3.5 CTDP-002 Clinical Trials
4.4 RO5256390 Drug Details
4.4.1 RO5256390 Current Status
4.4.2 RO5256390 Drug Overview
4.4.3 RO5256390 Mechanism of Action
4.4.4 RO5256390 Licensing/Collaboration Companies
4.4.5 RO5256390 Clinical Trials
4.5 Saxenda (liraglutide) Drug Details
4.5.1 Saxenda (liraglutide) Current Status
4.5.2 Saxenda (liraglutide) Drug Overview
4.5.3 Saxenda (liraglutide) Mechanism of Action
4.5.4 Saxenda (liraglutide) Licensing/Collaboration Companies
4.5.5 Saxenda (liraglutide) Clinical Trials
4.6 OMS527 Drug Details
4.6.1 OMS527 Current Status
4.6.2 OMS527 Drug Overview
4.6.3 OMS527 Mechanism of Action
4.6.4 OMS527 Licensing/Collaboration Companies
4.6.5 OMS527 Clinical Trials
4.7 Orexin-1 Antagonist for Binge Eating Disorder Drug Details
4.7.1 Orexin-1 Antagonist for Binge Eating Disorder Current Status
4.7.2 Orexin-1 Antagonist for Binge Eating Disorder Drug Overview
4.7.3 Orexin-1 Antagonist for Binge Eating Disorder Mechanism of Action
4.7.4 Orexin-1 Antagonist for Binge Eating Disorder Licensing/Collaboration Companies
4.7.5 Orexin-1 Antagonist for Binge Eating Disorder Clinical Trials
4.8 Orexin-1 Antagonist for Central Nervous System Disorders Drug Details
4.8.1 Orexin-1 Antagonist for Central Nervous System Disorders Current Status
4.8.2 Orexin-1 Antagonist for Central Nervous System Disorders Drug Overview
4.8.3 Orexin-1 Antagonist for Central Nervous System Disorders Mechanism of Action
4.8.4 Orexin-1 Antagonist for Central Nervous System Disorders Licensing/Collaboration Companies
4.8.5 Orexin-1 Antagonist for Central Nervous System Disorders Clinical Trials
4.9 dasotraline (SEP360-221) Drug Details
4.9.1 dasotraline (SEP360-221) Current Status
4.9.2 dasotraline (SEP360-221) Drug Overview
4.9.3 dasotraline (SEP360-221) Mechanism of Action
4.9.4 dasotraline (SEP360-221) Licensing/Collaboration Companies
4.9.5 dasotraline (SEP360-221) Clinical Trials
4.10 (Phentermine and topiramate) Drug Details
4.10.1 (Phentermine and topiramate) Current Status
4.10.2 (Phentermine and topiramate) Drug Overview
4.10.3 (Phentermine and topiramate) Mechanism of Action
4.10.4 (Phentermine and topiramate) Licensing/Collaboration Companies
4.10.5 (Phentermine and topiramate) Clinical Trials
5. LATEST BINGE EATING DISORDER PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Binge Eating Disorder Condition
2.3 Binge Eating Disorder Pipeline Snapshot, 2020
2.4 Companies investing in Binge Eating Disorder pipeline therapeutics
2.5 Phase wise Binge Eating Disorder Pipeline Candidates
2.6 Most Researched Mechanism of Action of Binge Eating Disorder Pipeline Products
2.7 Route of Administration of Binge Eating Disorder Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Amygdala Neurosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Chronos Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 F. Hoffmann-La Roche Ltd Overview, Contacts and ASD Pipeline Drugs
3.4 Novo Nordisk AS Overview, Contacts and ASD Pipeline Drugs
3.5 Omeros Corp Overview, Contacts and ASD Pipeline Drugs
3.6 OXonium Therapeutics Overview, Contacts and ASD Pipeline Drugs
3.7 Sosei Heptares Overview, Contacts and ASD Pipeline Drugs
3.8 Sunovion Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Vivus Inc Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 ANS-6637 Drug Details
4.1.1 ANS-6637 Current Status
4.1.2 ANS-6637 Drug Overview
4.1.3 ANS-6637 Mechanism of Action
4.1.4 ANS-6637 Licensing/Collaboration Companies
4.1.5 ANS-6637 Clinical Trials
4.2 CT-010018 Drug Details
4.2.1 CT-010018 Current Status
4.2.2 CT-010018 Drug Overview
4.2.3 CT-010018 Mechanism of Action
4.2.4 CT-010018 Licensing/Collaboration Companies
4.2.5 CT-010018 Clinical Trials
4.3 CTDP-002 Drug Details
4.3.1 CTDP-002 Current Status
4.3.2 CTDP-002 Drug Overview
4.3.3 CTDP-002 Mechanism of Action
4.3.4 CTDP-002 Licensing/Collaboration Companies
4.3.5 CTDP-002 Clinical Trials
4.4 RO5256390 Drug Details
4.4.1 RO5256390 Current Status
4.4.2 RO5256390 Drug Overview
4.4.3 RO5256390 Mechanism of Action
4.4.4 RO5256390 Licensing/Collaboration Companies
4.4.5 RO5256390 Clinical Trials
4.5 Saxenda (liraglutide) Drug Details
4.5.1 Saxenda (liraglutide) Current Status
4.5.2 Saxenda (liraglutide) Drug Overview
4.5.3 Saxenda (liraglutide) Mechanism of Action
4.5.4 Saxenda (liraglutide) Licensing/Collaboration Companies
4.5.5 Saxenda (liraglutide) Clinical Trials
4.6 OMS527 Drug Details
4.6.1 OMS527 Current Status
4.6.2 OMS527 Drug Overview
4.6.3 OMS527 Mechanism of Action
4.6.4 OMS527 Licensing/Collaboration Companies
4.6.5 OMS527 Clinical Trials
4.7 Orexin-1 Antagonist for Binge Eating Disorder Drug Details
4.7.1 Orexin-1 Antagonist for Binge Eating Disorder Current Status
4.7.2 Orexin-1 Antagonist for Binge Eating Disorder Drug Overview
4.7.3 Orexin-1 Antagonist for Binge Eating Disorder Mechanism of Action
4.7.4 Orexin-1 Antagonist for Binge Eating Disorder Licensing/Collaboration Companies
4.7.5 Orexin-1 Antagonist for Binge Eating Disorder Clinical Trials
4.8 Orexin-1 Antagonist for Central Nervous System Disorders Drug Details
4.8.1 Orexin-1 Antagonist for Central Nervous System Disorders Current Status
4.8.2 Orexin-1 Antagonist for Central Nervous System Disorders Drug Overview
4.8.3 Orexin-1 Antagonist for Central Nervous System Disorders Mechanism of Action
4.8.4 Orexin-1 Antagonist for Central Nervous System Disorders Licensing/Collaboration Companies
4.8.5 Orexin-1 Antagonist for Central Nervous System Disorders Clinical Trials
4.9 dasotraline (SEP360-221) Drug Details
4.9.1 dasotraline (SEP360-221) Current Status
4.9.2 dasotraline (SEP360-221) Drug Overview
4.9.3 dasotraline (SEP360-221) Mechanism of Action
4.9.4 dasotraline (SEP360-221) Licensing/Collaboration Companies
4.9.5 dasotraline (SEP360-221) Clinical Trials
4.10 (Phentermine and topiramate) Drug Details
4.10.1 (Phentermine and topiramate) Current Status
4.10.2 (Phentermine and topiramate) Drug Overview
4.10.3 (Phentermine and topiramate) Mechanism of Action
4.10.4 (Phentermine and topiramate) Licensing/Collaboration Companies
4.10.5 (Phentermine and topiramate) Clinical Trials
5. LATEST BINGE EATING DISORDER PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
